



6B 00/3806  
4



INVESTOR IN PEOPLE

## PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

REC'D 26 OCT 2000	
WIPO	PCT

The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.




Signed

Dated

13 OCT 2000



The  
Patent  
Office



RECEIVED EARLY/83-1 25/10/99

# Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road  
Newport  
Gwent NP9 1RH

04 OCT 1999

1. Your reference

JB/662/01

2. Patent application number

(The Patent Office will fill in this part)

9923381.9

3. Full name, address and postcode of the or of each applicant (underline all surnames)

JAN JORIS BROSENS  
29 CARTHEW ROAD, London W6 0DU  
UK

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its incorporation

7756163000

4. Title of the invention

THE USES OF CELL-SPECIFIC SPLICING IN GENE THERAPY

5. Name of your agent (if you have one)

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

Patents ADP number (if you know it)

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number  
(if you know it)

Date of filing  
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing  
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

NO

- a) any applicant named in part 3 is not an inventor, or
  - b) there is an inventor who is not named as an applicant, or
  - c) any named applicant is a corporate body.
- See note (d))

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description

Claim(s)

Abstract

Drawing(s)

6  
2  
1  
3 13

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

1  
1

11. I/We request the grant of a patent on the basis of this application.

Signature

Date 18/09/99

12. Name and daytime telephone number of person to contact in the United Kingdom

0181-741 9706  
(IAN BROSENS)

### Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

### Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

# Background

With the advent of molecular biology has come the ability to express nucleotide sequences of interest (NOI) within desirable cell types. For gene therapy protocols often such expression requires targeting to ensure that the desired NOI is expressed only within the appropriate cells. To date such targeting is achieved by either 'physical' means or use of transcriptional control or both.

Physical targeting can involve purification steps such that the resulting NOIs are delivered, post-purification, to the an enriched cell fraction such as CD34+ cells of blood. Other physical means by which targeting is achieved can be by way of using targeted NOI delivery vehicles (e.g. viral vectors or synthetic complexes) designed such to only deliver NOIs to the appropriate cell-type.

Transcriptional targeting often involves either synthetic or natural promoter elements designed to limit NOI expression to the appropriate cell types/ and or appropriate environment.

Although such cell/environment-specific targeting has great potential for treatment of human diseases and disorders there are still difficulties. For physical targeting, the desired cell-types can not always be enriched prior to NOI delivery. Furthermore targeted delivery vehicles are often inefficient in delivering NOI only to the desired cell type. For transcriptional targeting a major problem is that the synthetic or natural promoter elements, designed to confer cell/environment-specific NOI expression, are often 'leaky' resulting in expression of the NOI in cells other than the desired environment/cell type.

Presented here is a novel way by which targeting might be achieved in a cell/environment-specific manner. This invention involves the use of cell-type specific splicing events to limit NOI translation to desired cell types. This targeting strategy can therefore be considered both post-NOI delivery and post-NOI transcription in gene therapy protocols. It can, however, also be used in conjunction with other targeting strategies if so desired.

# Detailed outline of invention.

Although higher eukaryotic cells utilise promoter elements as the main method by which gene expression is restricted to desired cell types/environments, there are however other methods by which such expression can be regulated. One such method is at the level of post-transcription, and involves alternative splicing between cell types such that cell-type specific spliced transcripts are made, producing cell-type specific translated gene products. A well characterised example is the regulation of rat B-tropomyosin expression in muscle and non-muscle cells (see Balvay *et al* 1992 NAR 20: 3987-3992; Guo and Helfman 1993 NAR 21:4762-4768). In this case, exons 1-5, 8 and 9 are common to all mRNAs expressed from this gene. However in fibroblasts and smooth muscle cells exons 6 and 11 are used, whilst in skeletal muscle cells exons 7 and 10 are exclusively used. Studies of these splicing events have localised the critical elements for alternative splicing to sequences within exon 7 and the adjacent upstream intron. Moreover these sequences have been shown to confer cell type specific splicing when flanked with heterologous exons. For example Gou and Helfman (*i.b.i.d*) have shown that the rat B-tropomyosin exon 7 and its flanking intronic sequences are sufficient to regulate the suppression of exon 7 in non-muscle cells even when flanked by heterologous exons derived from adenovirus.

In part this invention relates to the use of these exon7/upstream intron regulatory sequences to restrict of gene expression to skeletal muscle cells. Outlined in **Figure 1A** is a representative diagram of a vector, in this instance pCI (Promega®) based, in which the pCI intron related sequences are replaced with the splice donor/flanking sequence (50 base pairs either side of the splice donor) from exon 5 of the rat B-tropomyosin gene and the splice acceptor/flanking sequence (from upstream of the branchpoint through 25 nucleotides downstream of exon 7) of the rat B-tropomyosin gene. Between these two sequences is inserted a luciferase gene taken from pGL3 (Promega®) with its open reading frame (ORF) orientated as shown. Downstream of all these sequences is located an enhanced green fluorescence protein (EGFP) ORF (Clontech®) as shown in **Figure 1A**. The poly A signal is as found downstream of the multiple cloning site of pCI. To ensure translation begins from the desired ATG (of either luciferase or

EGFP), upstream ATG sequences present in the primary transcript are mutated (in this instance by ATG to ACG mutagenesis). Such a vector can be made by established methods by those skilled in the art.

Because of the blockage in splicing conferred by exon 7 sequence in non-skeletal muscle cells, the resulting vector will produce unspliced transcripts in non-skeletal muscle cells (Figure 1B) and spliced transcripts in skeletal muscle cells (Figure 1C). As a consequence of this design, in skeletal muscle cells there is observed an increase in EGFP expression and a decrease in luciferase expression. In non-skeletal muscle there is instead an observed increase in luciferase expression and a decrease in EGFP expression. Consequently, in this example EGFP has skeletal muscle-specific high expression and luciferase has non-skeletal muscle-specific high expression. Of note is that although when unspliced, EGFP is still present within the RNA transcript, without the use of internal ribosome entry site sequences, ribosome translation will only lead to luciferase translation in a 5'-cap-dependent manner.

This example therefore demonstrates the potential for the use of *cis*-elements to limit expression of exogenous genes to specific cell-types. Although in this instance marker/reporter genes are used, these examples are not limiting. Other NOI of interest or of therapeutic value could be used instead.

This invention is however not limited to the use of intronic elements of the rat B-tropomyosin gene but this was shown by way of example of how exactly such an invention works. Aberrant or alternative splicing of specific mRNAs is a common occurrence in human malignancies and the products of such aberrant splicing events have been implicated in the oncogenesis and progression of human tumours. For instance malignancy associated aberrant/alternative splicing has been observed for the RNA message for TSG101 (Lin *et al* 1998 Br J. Haematol. 1998 102: 753-8; Lee and Feinberg 1997 Cancer Res. 57; 3131-4 ), cathepsin B (Mehtani *et al* 1998 J Biol Chem. 273 13236-44), epidermal growth factor receptor (eg. see Yamazaki *et al* J. Natl. Cancer Inst. 1998 90: 581-7; Sugawa *et al* 1990 PNAS: 87:8602-6), CD44 (see Kittl *et al* 1997 Exp. Clin. Immunogenet 14; 264-72; Sherman *et al* 1997 Cancer Res 57; 4889-97), NER (Saito *et al*

Oncogene 1997 14: 21), platelet-derived growth factor receptor (Mosselman *et al* 1996 PNAS 93; 2884-8), stem-cell factor receptor (Takaoka *et al* 1997 Cancer Lett. 115; 257 glucocorticoid receptors (Moalli and Rosen 1994 Leuk Lymphoma 15: 363-74), and p53 (Nakai *et al* 1994 Br. J. Haematol.). Often aberrant/alternative splicing of certain transcripts in human diseases is highly specific and the presence of these aberrant/alternative spliced transcripts can be used as molecular markers for the diagnosis of emerging or residual disease (see Taniguchi *et al* US patent 5643729 (assignees Boehringer Ingelheim))

An example of how such aberrant/alternative splicing events in human diseases can be exploited for transfer of NOIs in a cell-specific manner will now be outlined.

Progression of astrocytes from benign to a malignant phenotype (glioblastoma) is accompanied by a change in the RNA processing of fibroblast growth factor receptor-1 (FGFr) gene. The level of the high affinity form of the FGFr is dramatically increased due to  $\alpha$ -exon skipping during RNA splicing. The *cis*-regulatory sequence that confer this exon skipping have been elucidated (Cote *et al* 1997 J Biol. Chem. 272:1054-1060) by use of a vector construct termed pFGR17 (Cote *et al* 1997 *i.b.i.d.*). This construct was originally made by cloning the  $\alpha$ -exon,  $\gamma$ -exon and flanking sequence into intron 1 of the human metallothionein (hMT) gene. Consequently, transcripts produced from this vector, when spliced, have hMT exon-1,  $\alpha$ -exon, and hMT exon-2 of the mRNA joined. However if the inserted FGFr sequence induces exon skipping then  $\alpha$ -exon sequence would be excluded in the final mRNA message. Subsequent stepwise deletion of the inserted sequence demonstrated that a 375 nucleotide sequence inclusive and flanking that of the  $\alpha$ -exon was able to confer the exon skipping phenotype, provided that the overall insert size was maintained. These sequences had splice-functional *cis*-elements involved somehow in altering splicing in glioblastoma cells.

The pFGR-17 vector used to map the *cis* elements involved in FGFr exon skipping is the starting construct of this aspect of the invention- namely to generate glioblastoma-specific NOI translation/expression by conditional splicing (Figure 2A). Into the vector is first cloned a NOI, in this case the EGFP marker. This NOI is cloned downstream of the splice acceptor related



1 sequences of hMT-2 exon 2 pFGR-17. Next, to ensure that upon splicing, translation starts  
2 from EGFP ATG and not upstream ATGs found either within hMT-1 and hMT-2 sequence, such  
3 upstream ATGs are disabled by site-directed mutagenesis of ATG to ATTG. This vector can be  
4 made by established methods by those skilled in the art.

5  
6 In this instance the presence of ORFs within the  $\alpha$ -exon / flanking regions ensures that unless  
7 exon skipping occurs, EGFP is never translated. However in glioblastomas,  $\alpha$ -exon induced  
8 skipping leads to upstream ORF removal and subsequently EGFP is then the first ORF of the  
9 transcript and translated as such. The process of exon skipping is restricted to malignant cells  
10 and hence EGFP expression is confined to glioblastoma cells (**Figure 2C**) and fails to occur in  
11 healthy astrocytes (**Figure 2B**). Although in this instance a marker gene (EGFP) is used, this  
12 examples is not limiting. Other NOI of interest or of therapeutic value could replace EGFP,  
13 using established methods by those skilled in the art.

14  
15 These two examples demonstrate how the use of aberrant or alternative splicing can be exploited  
16 to restrict gene expression to certain environments and cell types. They aid in understanding the  
17 current invention but the invention is not limited to the use of these two preferred embodiments.  
18 The use of this invention include, but are not limited to, *in-vivo* and *ex-vivo* therapeutic regimes  
19 as currently undertaken in gene therapy and gene delivery protocols.

20  
21 For the development of other cell-type specific splicing vectors in manners similar to that  
22 described above, the *cis*-elements in the transcript that confer cell-specific splicing may require  
23 characterisation. This can be done prior to construction of the cell-type splicing specific NOI-  
24 delivery vehicle by methodology known in the art; by way of example methodology see Cote *et*  
25 *al* (1997 J Biol. Chem. 272:1054-1060), Balvay *et al* (1992 NAR 20: 3987-3992) and Guo and  
26 Helfman 1993 (NAR 21:4762-4768).

27  
28 Alternatively, cell-type specific splicing elements can be identified by a novel approach using  
29 original genomic DNA libraries. By way of example (**Figure 3**), a gene expression screen is  
30 developed whereby a selectable marker is placed within an intron and, hence, will not expressed

1 unless splicing is inhibited. Downstream of the selectable marker is then cloned a sheared  
2 genomic library. The library is then introduced into a desirable cell population, desirable  
3 stimulus performed and subsequent marker expressing cells identified. Desirable stimuli might  
4 include mitogen/oncogene stimulation of the cell population prior to selection such that  
5 sequences are identified within positive cells that confer mitogen-specific splicing inhibition.

## Claims

1 The use of rat B-tropomyosin exon 5 splice donor (and surrounding functional sequence) and/or the use of rat B-tropomyosin exon 7 splice acceptor (and surrounding functional sequence) to confer cell specific splicing events that limit optimal NOI translation/expression to either skeletal muscle or non-muscle cells. The NOI delivery vector maybe of any type: Plasmid-based vectors, retroviral based vectors, lentiviral-based vectors, adenoviral based vectors and combinations of such are example such NOI delivery vectors. The promoter and polyadenylation signals used to mediate the transcription of the RNA transcripts as described can be of any origin.

2 The use of B-tropomyosin exon 5 splice donor (and surrounding splice-functional sequence) from any species and/or the use of B-tropomyosin exon 7 splice acceptor (and surrounding splice-functional sequence) from any species to confer cell specific splicing events that limit optimal NOI translation/expression to either muscle or non-muscle cells. The NOI delivery vector maybe of any type: Plasmid-based vectors, retroviral based vectors, lentiviral-based vectors, adenoviral based vectors and combinations of such are examples. The promoter and polyadenylation signals used to mediate the transcription of the RNA transcripts as described can be of any origin.

3 The use of human FGFR  $\alpha$ -exon (and surrounding splice-functional sequence) to confer cell specific splicing events that limit optimal NOI translation/expression to glioblastoma related/derived cells. The NOI delivery vector maybe of any type: Plasmid-based vectors, retroviral based vectors, lentiviral-based vectors, adenoviral based vectors and combinations of such are example. The promoter and polyadenylation signals used to mediate the transcription of the RNA transcripts as described can be of any origin.

3 The use FGFR  $\alpha$ -exon (and surrounding splice-functional sequence) from any species to confer cell specific splicing events that limit optimal NOI translation/expression to glioblastoma related/derived cells. The NOI delivery vector maybe of any type: Plasmid-based vectors,

retroviral based vectors, lentiviral-based vectors, adenoviral based vectors and combinations of such are examples. The promoter and polyadenylation signals used to mediate the transcription of the RNA transcripts as described can be of any origin.

5 The use of any invention according to claims 1-4 whereby removal/mutation of any unrequired upstream ATG translation initiation sites is used to ensure translation initiation at the desired ATG such that the NOI translation/expression is optimal.

6 The use of other splice sites and surrounding splice-functional elements from any origin (either natural or synthetic) in a manner and configuration similar to that described for examples 1 and 2 of the text to confer cell type specific splicing such that NOI optimal translational/expression is restricted to specific cell types and/or environment.

7 The use of libraries as outlined in the text to identify sequence elements capable of conferring cell specific splicing of desirable nature.

8 The use of the invention according to claims 1-7 when used to in conjunction with other methodologies, protocols and regimes for the treatment of diseases and disorders.

---

1

### 3 The uses of cell-specific splicing in gene therapy

4

#### 5 Abstract

6


7

8 This invention relates to the construction of eukaryotic expression vectors. In particular this  
9 invention relates to the use of a novel methodology to regulate cell/environment-specific  
10 expression of such vectors. More particularly, this invention relates to the use of splicing  
11 elements within such vectors to restrict desired gene translation/expression to desired  
12 environments/cell types in the treatment of human diseases and disorders.


13




(A)



(B)




(C)








(A)



(B)



(C)







Figure 3



PCT / GB00 / 03806

Frank B Dehn + Co.

5/10/00.

(Tracey Carter)